This study evaluates whether it is safe to administer a helper peptide vaccine with
dabrafenib and trametinib. This study will also evaluate the effects of the combination of
the peptide vaccine and dabrafenib and trametinib on the immune system. We will monitor
these effects by performing tests in the laboratory on participants' blood, a lymph node,
and tumor samples.
- Participants with measurable stage IIIB, IIIC, or IV melanoma that have clinical or
radiological evidence of disease. These participants may have had cutaneous, uveal,
mucosal primary melanoma, or an unknown primary melanoma. Staging must be confirmed
by cytological or histological examination. Staging of cutaneous melanoma will be
based on the revised AJCC staging system.
- Participants must be eligible to be treated with BRAF inhibitor and MEK inhibitor
- Participants will be required to have radiological studies to define radiologically
evident disease. Required studies include:
- Chest CT scan,
- Abdominal and pelvic CT scan, and
- Head CT scan or MRI
- Participants who have metastatic melanoma available for biopsy pretreatment and on
day 22 must consent to having those biopsies. These metastases may be in nodes, skin,
soft tissue, liver, or other sites that can be accessed by needle biopsy, incisional
or excisional biopsy, with or without image guidance.
- Participants who have had brain metastases will be eligible if all of the following
- The total number of brain metastases ever ≤ 3
- Each brain metastasis must have been completely removed by surgery or each
unresected brain metastasis must have been treated with stereotactic
- There has been no evident growth of any brain metastasis since the most recent
- No brain metastasis is > 2 cm in diameter at the time of registration
- The most recent surgical resections or gamma-knife therapy for malignant
melanoma must have been completed ≥ 1 week and ≤ 6 months prior to registration.
- ECOG performance status of 0 or 1
- Participants must have the ability and willingness to give informed consent
- Laboratory parameters as follows:
- ANC > 1000/mm3
- Platelets > 100,000/mm3
- Hgb > 9 g/dL
- HgB-A1c ≤ 7.5%
- AST and ALT up to 2.5 x upper limits of normal (ULN). Patients known to have
Gilbert's disease may be eligible with AST and ALT up to 5 x ULN.
- Bilirubin up to 2.5 x ULN
- Alkaline phosphatase up to 2.5 x ULN.
- Creatinine up to 1.5 x ULN
- Age 18 years or older at registration
- Participants must have at least two intact (undissected) axillary and/or inguinal
lymph node basins
- Participants who have received the following medications or treatments at any time
within 4 weeks of registration:
- • Chemotherapy
- Interferon (e.g. Intron-A®)
- Radiation therapy (Stereotactic radiotherapy, such as gamma knife, can be used ≥
1 week and ≤ 6 months prior to registration)
- Allergy desensitization injections
- Corticosteroids, administered transdermally, parenterally or orally. Inhaled
steroids (e.g.: Advair®, Flovent®, Azmacort®) are not permitted. Topical
corticosteroids are acceptable.
- Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)
- Interleukins (e.g. Proleukin®)
- Any investigational medication
- Targeted therapies specific for mutated BRAF
- MEK inhibitor
- HIV positivity or evidence of active Hepatitis C virus.
- Participants who are currently receiving nitrosoureas or who have received this
therapy 6 weeks prior to registration
- Participants who are currently receiving a checkpoint molecule blockade therapy, or
who have received this therapy within 3weeks prior to registration.
- Participants with known or suspected allergies to any component of the vaccine.
- Participants may not have been vaccinated previously with any of the synthetic
peptides included in this protocol. Participants who have received vaccinations
containing agents other than the synthetic peptides included in this protocol and
have recurred during or after administration of the vaccine will be eligible to
enroll 12 weeks following their last vaccination.
- Female participants must not be breastfeeding
- Participants in whom there is a medical contraindication or potential problem in
complying with the requirements of the protocol in the opinion of the investigator.
- Participants classified according to the New York Heart Association classification as
having Class III or IV heart disease.
- Participants with uncontrolled diabetes, defined as having a HgB-A1c greater than
- Participants must not have had prior autoimmune disorders requiring cytotoxic or
immunosuppressive therapy, or autoimmune disorders with visceral involvement.
Participants with an active autoimmune disorder requiring these therapies are also
- Participants who have another cancer diagnosis, except that the following diagnoses
will be allowed:
- squamous cell cancer of the skin without known metastasis
- basal cell cancer of the skin without known metastasis
- carcinoma in situ of the breast (DCIS or LCIS)
- carcinoma in situ of the cervix
- any cancer without distant metastasis that has been treated successfully,
without evidence of recurrence or metastasis for over 3 years
- Participants with known addiction to alcohol or drugs who are actively taking those
agents, or participants with recent (within 1 year of registration) or ongoing
illicit IV drug use.
- Body weight < 110 pounds
- Participants with a known history of glucose-6-phosphate dehydrogenase deficiency.